fig1
![MAFLD under the lens: the role of gut microbiota](https://image.oaes.cc/32956067-07a4-4f5b-b9a4-c2a929a7f140/5197.fig.1.jpg)
Figure 1. Step-by-step acquisition of unhealthy patterns of gut dysbiosis with the severity of liver disease in patients with MAFLD. TMAO: Trimethylamine-N-oxide; MAFLD: metabolic-associated fatty liver disease; HCC: hepatocellular carcinoma; LPS: lipopolysaccharides; SCFA: short-chain fatty acids.